BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tatenuma T, Kawahara T, Hayashi N, Hasumi H, Makiyama K, Nakaigawa N, Kishida T, Miyoshi Y, Yao M, Uemura H. The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer. Biomed Res Int 2019;2019:2535270. [PMID: 31781602 DOI: 10.1155/2019/2535270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Tian S, Lei Z, Gong Z, Sun Z, Xu D, Piao M. Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review. Cancer Cell Int 2020;20:409. [PMID: 32863768 DOI: 10.1186/s12935-020-01508-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kawahara T, Kato M, Tabata K, Kojima I, Yamada H, Kamihira O, Tsumura H, Iwamura M, Uemura H, Miyoshi Y. A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment. BMC Cancer 2020;20:919. [PMID: 32977754 DOI: 10.1186/s12885-020-07410-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]